Letermovir for Primary Prophylaxis of Cytomegalovirus Infection After R+HID-HSCT
Condition: The Incidence of Peripheral Blood CMV Activation and Confirmed Clinically Significant CMV Infection Within 24 Weeks After Transplantation Intervention: Drug: Letermovir Sponsor: Institute of Hematology & Blood Diseases Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials
Clinical Study of High Concentration Ganciclovir Eye Drops in the Treatment of Cytomegalovirus Retinitis
Conditions: Cytomegalovirus Retinitis; Ganciclovir Eye Drops Intervention: Drug: 2% Ganciclovir Eye Drops Sponsor: Tianjin Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials
Letermovir for Primary Prophylaxis of Cytomegalovirus Infection After R+HID-HSCT
Condition: The Incidence of Peripheral Blood CMV Activation and Confirmed Clinically Significant CMV Infection Within 24 Weeks After Transplantation Intervention: Drug: Letermovir Sponsor: Institute of Hematology & Blood Diseases Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials
Clinical Study of High Concentration Ganciclovir Eye Drops in the Treatment of Cytomegalovirus Retinitis
Conditions: Cytomegalovirus Retinitis; Ganciclovir Eye Drops Intervention: Drug: 2% Ganciclovir Eye Drops Sponsor: Tianjin Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials
Letermovir for Primary Prophylaxis of Cytomegalovirus Infection After R+HID-HSCT
Condition: The Incidence of Peripheral Blood CMV Activation and Confirmed Clinically Significant CMV Infection Within 24 Weeks After Transplantation Intervention: Drug: Letermovir Sponsor: Institute of Hematology & Blood Diseases Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials
Clinical Study of High Concentration Ganciclovir Eye Drops in the Treatment of Cytomegalovirus Retinitis
Conditions: Cytomegalovirus Retinitis; Ganciclovir Eye Drops Intervention: Drug: 2% Ganciclovir Eye Drops Sponsor: Tianjin Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials
Letermovir for Primary Prophylaxis of Cytomegalovirus Infection After R+HID-HSCT
Condition: The Incidence of Peripheral Blood CMV Activation and Confirmed Clinically Significant CMV Infection Within 24 Weeks After Transplantation Intervention: Drug: Letermovir Sponsor: Institute of Hematology & Blood Diseases Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials
Clinical Study of High Concentration Ganciclovir Eye Drops in the Treatment of Cytomegalovirus Retinitis
Conditions: Cytomegalovirus Retinitis; Ganciclovir Eye Drops Intervention: Drug: 2% Ganciclovir Eye Drops Sponsor: Tianjin Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials
Letermovir for Primary Prophylaxis of Cytomegalovirus Infection After R+HID-HSCT
Condition: The Incidence of Peripheral Blood CMV Activation and Confirmed Clinically Significant CMV Infection Within 24 Weeks After Transplantation Intervention: Drug: Letermovir Sponsor: Institute of Hematology & Blood Diseases Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials
Clinical Study of High Concentration Ganciclovir Eye Drops in the Treatment of Cytomegalovirus Retinitis
Conditions: Cytomegalovirus Retinitis; Ganciclovir Eye Drops Intervention: Drug: 2% Ganciclovir Eye Drops Sponsor: Tianjin Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials
Letermovir for Primary Prophylaxis of Cytomegalovirus Infection After R+HID-HSCT
Condition: The Incidence of Peripheral Blood CMV Activation and Confirmed Clinically Significant CMV Infection Within 24 Weeks After Transplantation Intervention: Drug: Letermovir Sponsor: Institute of Hematology & Blood Diseases Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials
Clinical Study of High Concentration Ganciclovir Eye Drops in the Treatment of Cytomegalovirus Retinitis
Conditions: Cytomegalovirus Retinitis; Ganciclovir Eye Drops Intervention: Drug: 2% Ganciclovir Eye Drops Sponsor: Tianjin Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials
Letermovir for Primary Prophylaxis of Cytomegalovirus Infection After R+HID-HSCT
Condition: The Incidence of Peripheral Blood CMV Activation and Confirmed Clinically Significant CMV Infection Within 24 Weeks After Transplantation Intervention: Drug: Letermovir Sponsor: Institute of Hematology & Blood Diseases Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials
Clinical Study of High Concentration Ganciclovir Eye Drops in the Treatment of Cytomegalovirus Retinitis
Conditions: Cytomegalovirus Retinitis; Ganciclovir Eye Drops Intervention: Drug: 2% Ganciclovir Eye Drops Sponsor: Tianjin Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials
Letermovir for Primary Prophylaxis of Cytomegalovirus Infection After R+HID-HSCT
Condition: The Incidence of Peripheral Blood CMV Activation and Confirmed Clinically Significant CMV Infection Within 24 Weeks After Transplantation Intervention: Drug: Letermovir Sponsor: Institute of Hematology & Blood Diseases Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials
